Tolerance is the key to understanding antimalarial drug resistance

被引:60
作者
Hastings, IM [1 ]
Watkins, WM [1 ]
机构
[1] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England
关键词
D O I
10.1016/j.pt.2005.12.011
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
The evolution of antimalarial drug resistance is often considered to be a single-stage process in which parasites are either fully resistant or completely sensitive to a drug. However, this does not take into account the important intermediate stage of drug tolerance. Drug-tolerant parasites are killed by the high serum concentrations of drugs that occur during direct treatment of the human host. However, these parasites can spread in the human population because many drugs persist long after treatment, and the tolerant parasites can infect people in which there are residual levels of the drugs. This intermediate stage between fully sensitive and fully resistant parasites has far-reaching implications for the evolution of drug-resistant malaria.
引用
收藏
页码:71 / 77
页数:7
相关论文
共 47 条
[21]   How species evolve collectively: implications of gene flow and selection for the spread of advantageous alleles [J].
Morjan, CL ;
Rieseberg, LH .
MOLECULAR ECOLOGY, 2004, 13 (06) :1341-1356
[22]   A selective sweep driven by pyrimethamine treatment in southeast Asian malaria parasites [J].
Nair, S ;
Williams, JT ;
Brockman, A ;
Paiphun, L ;
Mayxay, M ;
Newton, PN ;
Guthmann, JP ;
Smithuis, FM ;
Hien, TT ;
White, NJ ;
Nosten, F ;
Anderson, TJC .
MOLECULAR BIOLOGY AND EVOLUTION, 2003, 20 (09) :1526-1536
[23]   Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet? [J].
Nzila, A ;
Ochong, E ;
Nduati, E ;
Gilbert, K ;
Winstanley, P ;
Ward, S ;
Marsh, K .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2005, 99 (05) :341-346
[24]   Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethaminel/sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum [J].
Nzila, AM ;
Nduati, E ;
Mberu, EK ;
Sibley, CH ;
Monks, SA ;
Winstanley, PA ;
Watkins, WM .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (06) :2023-2028
[25]   Kenyan Plasmodium falciparum field isolates:: Correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain [J].
Nzila-Mounda, A ;
Mberu, EK ;
Sibley, CH ;
Plowe, CV ;
Winstanley, PA ;
Watkins, WM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (01) :164-169
[26]  
Peters W., 1987, CHEMOTHERAPY DRUG RE
[27]   Drug resistant falciparum malaria: clinical consequences and strategies for prevention [J].
Price, RN ;
Nosten, F .
DRUG RESISTANCE UPDATES, 2001, 4 (03) :187-196
[28]   Antifolate antimalarial resistance in southeast Africa: a population-based analysis [J].
Roper, C ;
Pearce, R ;
Bredenkamp, B ;
Gumede, J ;
Drakeley, C ;
Mosha, F ;
Chandramohan, D ;
Sharp, B .
LANCET, 2003, 361 (9364) :1174-1181
[29]   Intercontinental spread of pyrimethamine-resistant malaria [J].
Roper, C ;
Pearce, R ;
Nair, S ;
Sharp, B ;
Nosten, F ;
Anderson, T .
SCIENCE, 2004, 305 (5687) :1124-1124
[30]   Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum:: what next? [J].
Sibley, CH ;
Hyde, JE ;
Sims, PFG ;
Plowe, CV ;
Kublin, JG ;
Mberu, EK ;
Cowman, AF ;
Winstanley, PA ;
Watkins, WM ;
Nzila, AM .
TRENDS IN PARASITOLOGY, 2001, 17 (12) :582-588